PLANTATION, Fla., Oct. 4, 2005 (PRIMEZONE) -- MEDirect Latino Inc. (Pink Sheets:MLTO) (http://www.medirectlatino.org), today announced that The Research Works, Inc. has released an analyst research report covering the company with an initial price target of $14.00. The report is now available for review at: http://www.stocksontheweb.com/mlto.pdf
"The Research Works was chosen to evaluate MEDirect Latino due to the reputation of the company's president, Mr. William J. Ritger, and the in-depth knowledge he has of the health care sector. Few analysts have the historical knowledge and deep insight in the microcap space as does Mr. Ritger. During his career, Bill has analyzed hundreds of microcap and small cap companies and has proven himself to be extraordinarily knowledgeable in this underserved, but opportunity-rich market," stated Mr. Raymond J. Talarico, CEO and co-chairman of the board of MEDirect Latino.
The Research Works is an equity research boutique founded in 1992 that focuses on small cap, microcap, and penny stocks. The Research Works' stated objective is to discover undervalued small companies and help them achieve fair value for their stocks by producing high-quality, paid research reports that are grounded in fundamental analysis and employ state-of-the-art equity valuation models. The Research Works targets a far-reaching network of sophisticated, self-directed investors and distributes its research through a strong Internet presence and a large direct distribution list.
"We believe that the Research Works report and the recent updated analytical valuation study by Wall Street Research, clearly shows that our stock is grossly undervalued. As we continue to educate the market about the MEDirect Latino business model, coupled with the upcoming announcement of our September operating results on October 10th, we continue to validate our projections and earning estimates. MEDirect Latino's monthly revenue increases are bringing additional attention to the Company, as the only national provider focused on the Medicare eligible Hispanic marketplace," added Mr. Talarico.
About MEDirect Latino:
MEDirect Latino (Pink Sheets:MLTO) (www.medirectlatino.org) is a rapidly growing, uniquely positioned provider of direct-to-consumer Medicare reimbursed medical products focused exclusively on chronic diseases afflicting the Hispanic community in the United States and Puerto Rico. MEDirect is the only company positioned to serve the U.S. Hispanic health care market as a direct-to-consumer Medicare provider on an authentically national level. The company's current focus is the distribution of products for the treatment of Type II diabetes specifically because of its disproportionate impact and increasing diagnosis rate within the U.S. Hispanic population, noting an incidence of 120 percent higher than among non-Hispanic whites. Type II diabetes was also targeted because of its unique status within the Medicare reimbursement regime and because of its high degree of correlation to other chronic conditions such as high blood pressure and heart disease. These other conditions represent considerable future market potential that will allow MEDirect to efficiently scale its model by leveraging its existing client base and infrastructure.
The current Hispanic market for MEDirect's products is conservatively estimated at approximately $748 million in the continental United States. The size of the opportunity is understated by such figures as an estimated 1.2 million of the over 4.1 million Hispanics in the United States over 65 eligible to receive Medicare benefits are currently collecting these benefits with an estimate that over 1.4 million of those Medicare-eligible Hispanics have diabetes (implying a potential continental U.S. market for MEDirect products of approximately $1 billion).
The MEDirect Latino Inc. logo is available at: http://www.primezone.com/newsroom/prs/?pkgid=1873
Safe Harbor Disclosure:
This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "looking ahead," "anticipates," "estimates," and other terms with similar meaning. Although the company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the company's projections and expectations are disclosed in the company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.
About Research Works
Disclosures: This report was prepared by The Research Works, Inc. ("RW"), a New Jersey-based equity research boutique (www.stocksontheweb.com). Effective September 23, 2005, in consideration for RW's equity research services relating to this company, including this report, to be performed through October 2, 2006, the company agreed to pay RW a fee of 75,000 shares of the company's common stock (restricted). Terms under which all or a percentage of this fee is refundable are outlined in RW's ADV filing posted at www.stocksontheweb.com. This report is based on RW's independent analysis and judgment. The materials upon which the information in this report is based were supplied by the company and other sources believed by RW to be reliable; except as otherwise indicated, RW has made no independent verification and does not guarantee the information's accuracy or completeness. Any interpretations, earnings estimates, and conclusions contained in this report are those of RW. This report is not intended to constitute a recommendation for any particular investor to purchase or sell any particular security or that any particular security is suitable for any particular investor. This report should not be construed as a recommendation or request to engage in any transaction, or an offer, or solicitation of an offer, to buy or sell any security or investment, and investors are advised to consult their personal broker or investment advisor before making any investment decision concerning any of the companies mentioned herein. Use of this report may be subject to applicable rules of any self-regulatory organization of which you may be a member. The information contained in this report is subject to change without notice, and RW assumes no responsibility to update the information contained in this report. Subject to certain restrictions outlined in Part II of RW's Investment Advisor ADV filing, a copy of which is posted on RW's web site, RW and its affiliated entities and persons may purchase and hold positions in the securities of its clients, but they are prohibited from selling any securities of a RW client during the RW service period to such client. The Research Works, Inc.(c) 2005. All rights reserved. Additional and supporting information is available upon request.